Edition:
United Kingdom

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

6.84USD
20 Apr 2018
Change (% chg)

$-0.01 (-0.15%)
Prev Close
$6.85
Open
$6.85
Day's High
$6.90
Day's Low
$6.77
Volume
22,964
Avg. Vol
47,973
52-wk High
$10.00
52-wk Low
$3.21

Chart for

About

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including... (more)

Overall

Beta: -1.40
Market Cap(Mil.): $94.27
Shares Outstanding(Mil.): 27.48
Dividend: --
Yield (%): --

Financials

  ZFGN.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.88 -- --
ROI: -42.22 1.58 14.38
ROE: -42.56 2.41 16.07

BRIEF-Zafgen Reports Q4 Loss Per Share $0.48

* ZAFGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; ANNOUNCES POSITIVE INTERIM DATA FROM ONGOING ZGN-1061 PHASE 2 PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH TYPE 2 DIABETES

06 Mar 2018

BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln

* ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING Source text: [http://bit.ly/2Earwn6] Further company coverage:

05 Jan 2018

BRIEF-Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018

* ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018

05 Jan 2018

BRIEF-Zafgen reports Q3 loss per share $0.46

* Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

07 Nov 2017

Earnings vs. Estimates